The stock has a 36-month beta value of -0.63. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IMRX is 20.63M, and at present, short sellers hold a 13.94% of that float. On April 24, 2024, the average trading volume of IMRX was 686.19K shares.
IMRX) stock’s latest price update
Immuneering Corp (NASDAQ: IMRX) has experienced a decline in its stock price by -5.23 compared to its previous closing price of 1.72. However, the company has seen a fall of -11.41% in its stock price over the last five trading days. Seeking Alpha reported 2024-03-19 that Positive safety and anti-tumor activity released from phase 1 portion of phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors. Additional expansion cohort results from the phase 2 portion of the phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors, expected later in 2024. IMM-6-415 is another MAPK pathway targeting drug, but is able to target either RAS or RAF solid tumors; Dosing of first patient in phase 1 study expected in March 2024.
IMRX’s Market Performance
IMRX’s stock has fallen by -11.41% in the past week, with a monthly drop of -36.08% and a quarterly drop of -72.18%. The volatility ratio for the week is 9.27% while the volatility levels for the last 30 days are 10.64% for Immuneering Corp The simple moving average for the past 20 days is -25.63% for IMRX’s stock, with a -75.75% simple moving average for the past 200 days.
Analysts’ Opinion of IMRX
Many brokerage firms have already submitted their reports for IMRX stocks, with Needham repeating the rating for IMRX by listing it as a “Buy.” The predicted price for IMRX in the upcoming period, according to Needham is $15 based on the research report published on March 15, 2024 of the current year 2024.
Jefferies gave a rating of “Hold” to IMRX, setting the target price at $3 in the report published on March 15th of the current year.
IMRX Trading at -60.87% from the 50-Day Moving Average
After a stumble in the market that brought IMRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.59% of loss for the given period.
Volatility was left at 10.64%, however, over the last 30 days, the volatility rate increased by 9.27%, as shares sank -35.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -75.34% lower at present.
During the last 5 trading sessions, IMRX fell by -11.41%, which changed the moving average for the period of 200-days by -83.52% in comparison to the 20-day moving average, which settled at $2.1467. In addition, Immuneering Corp saw -77.82% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMRX starting from Cormorant Asset Management, LP, who sale 400,000 shares at the price of $2.90 back on Apr 01 ’24. After this action, Cormorant Asset Management, LP now owns 2,895,273 shares of Immuneering Corp, valued at $1,160,181 using the latest closing price.
Feinberg Peter, the Director of Immuneering Corp, purchase 25,000 shares at $2.55 during a trade that took place back on Mar 22 ’24, which means that Feinberg Peter is holding 111,766 shares at $63,713 based on the most recent closing price.
Stock Fundamentals for IMRX
Current profitability levels for the company are sitting at:
- -0.62 for the present operating margin
- 0.99 for the gross margin
The net margin for Immuneering Corp stands at 10.82. The total capital return value is set at -0.62. Equity return is now at value -53.36, with -47.54 for asset returns.
Based on Immuneering Corp (IMRX), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -10.97. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is 0.05.
Currently, EBITDA for the company is -57.65 million with net debt to EBITDA at 0.0. When we switch over and look at the enterprise to sales, we see a ratio of -0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.35.
Conclusion
To sum up, Immuneering Corp (IMRX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
